News

GlobalData on MSN23h

BMS’ Phase III trial of Reblozyl misses primary endpoint

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated ...